TANDem-2: Closing the Gap to Interventions for TAND
Launched by VRIJE UNIVERSITEIT BRUSSEL · Mar 13, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The TANDem-2 trial is a study designed to help adult caregivers of individuals with Tuberous Sclerosis Complex (TSC), a condition that can cause various health issues. The main focus of this pilot study is to see if a short online program called "Well-Beans for Caregivers" can be easily offered to caregivers, how they feel about participating in it, and whether it makes a positive difference in their well-being.
To be eligible for this study, you need to be an adult caregiver for someone with TSC, regardless of the individual's age. The program is still in the planning stages and has not yet started recruiting participants. If you decide to join, you can expect to engage in a brief, supportive program aimed at improving your experience as a caregiver. This study is an important step in understanding how to better support caregivers like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult caregiver of an individual with Tuberous Sclerosis Complex (TSC) of any age
- Exclusion Criteria:
- • Not an adult caregiver of an individual with TSC
About Vrije Universiteit Brussel
The Vrije Universiteit Brussel (VUB) is a distinguished research university located in Brussels, Belgium, known for its commitment to innovative education and cutting-edge research across various disciplines. As a clinical trial sponsor, VUB actively engages in advancing medical knowledge and improving patient care through rigorous scientific investigations. The university fosters collaborations with healthcare institutions and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. VUB's research initiatives are driven by a multidisciplinary approach, leveraging expertise from fields such as medicine, health sciences, and biomedical engineering to address pressing health challenges and contribute to the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anna Jansen, MD, PhD
Principal Investigator
Vrije Universiteit Brussel
Petrus J de Vries, MD PhD
Principal Investigator
University of Cape Town
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported